Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

About this update from Myriad Genetics, Inc.

[{"type":"image","alt":"Myriad Genetics, Inc.","displaySize":"","headline":null,"caption":"Myriad Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_y5LWpbQjZzzOJzKUH_nTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf","width":300,"height":138}},"lazy":false},{"type":"text","content":"Highlights","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter 2025 revenue of $209.8 million was consistent with fourth quarter 2024 revenue, but grew 4% year-over-year when excluding the previously discussed headwind1 of $8.1 million.","length":188,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year 2025 revenue of $824.5 million decreased 2% year-over-year. Excluding headwinds2, full year 2025 revenue grew 2% year-over-year. ","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary cancer testing at 9%, and GeneSight at 9%. ","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth quarter 2025 gross margin was 70.0% and in-line with third quarter 2025. ","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth quarter 2025 GAAP net loss of $7.9 million, or $0.08 per share, while adjusted EPS was $0.04 per share and adjusted EBITDA was $14.3 million.","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":717,"olType":false},{"type":"text","content":"SALT LAKE CITY, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced financial results for its fourth quarter ended December 31, 2025, and reaffirmed its financial guidance on business performance for the full-year 2026.","length":325,"tagName":"p"},{"type":"text","content":""We ended 2025 with positive momentum in a number of key areas, including within the Cancer Care Continuum where we drove another quarter of high single-digit volume growth in Hereditary cancer testing year-over-year and recognized improving volum...

More updates from Myriad Genetics, Inc.